US20110257134A1 - CO-CRYSTALS OF TRAMADOL AND NSAIDs - Google Patents

CO-CRYSTALS OF TRAMADOL AND NSAIDs Download PDF

Info

Publication number
US20110257134A1
US20110257134A1 US13/124,027 US200913124027A US2011257134A1 US 20110257134 A1 US20110257134 A1 US 20110257134A1 US 200913124027 A US200913124027 A US 200913124027A US 2011257134 A1 US2011257134 A1 US 2011257134A1
Authority
US
United States
Prior art keywords
tramadol
crystal
naproxen
free base
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/124,027
Other languages
English (en)
Inventor
Helmut Heinrich Buschmann
Lluis Sola Carandell
Jordi Benet Buchholz
Jordi Carles Ceron Bertran
Carlos Ramon Plata Salaman
Nicolas Tesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Assigned to LABORATORIOS DEL DR. ESTEVE, S.A. reassignment LABORATORIOS DEL DR. ESTEVE, S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BENET BUCHHOLZ, JORDI, BUSCHMANN, HELMUT HEINRICH, Ceron Bertran, Jordi Carles, PLATA SALAMAN, CARLOS RAMON, SOLA CARANDELL, LLUIS, TESSON, NICOLAS
Publication of US20110257134A1 publication Critical patent/US20110257134A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the present invention relates to co-crystals of tramadol and NSAIDs (Non steroidal anti-inflammatory drugs), processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
  • NSAIDs Non steroidal anti-inflammatory drugs
  • Pain is a complex response that has been functionally categorized into sensory, autonomic, motor, and affective components.
  • the sensory aspect includes information about stimulus location and intensity while the adaptive component may be considered to be the activation of endogenous pain modulation and motor planning for escape responses.
  • the affective component appears to include evaluation of pain unpleasantness and stimulus threat as well as negative emotions triggered by memory and context of the painful stimulus.
  • Chronic pain includes neuropathic pain and chronic inflammatory pain, for example arthritis, or pain of unknown origin, as fibromyalgia.
  • Acute pain usually follows non-neural tissue injury, for example tissue damage from surgery or inflammation, or migraine.
  • Opioids are frequently used as analgesics in pain.
  • Derivatives of morphine are indicated for the treatment of moderate to acute pain in human.
  • the analgesic effect is obtained through their action on morphinic receptors, preferably the p-receptors.
  • morphinic receptors preferably the p-receptors.
  • these derivatives of morphine may be mentioned morphine, codeine, pethidine, dextropropoxyphenemethadone, lenefopan and others.
  • Tramadol also available as a physiologically acceptable salt, particularly as a chlorohydrate.
  • Tramadol whose chemical name is 2-(dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexanol, has the following formula:
  • This structure shows two different chiral centers and thus may exist in different diastereoisomers among which the tramadol is the cis-diastereoisomer: (1R,2R), or (1S,2S), both also known as (+)-tramadol and ( ⁇ )-tramadol and both of which contribute in different ways to its activity.
  • tramadol is an opioid agonist, whereas clinical experience indicates that it lacks many of the typical side effects of opioids agonist, for example respiratory depression, constipation or tolerance.
  • opioids cannot always be given repeatedly or at higher doses as analgesics to treat pain.
  • the side effects of opioids are known in the art including e.g. J. Jaffe in “Goodman and Gilman's, The Pharmacological Basis of Therapeutics”, 8 th edition; Gilman et al.; Pergamon Press, New York, 1990, Chapter 22, pages 522-573.
  • tramadol base or hydrochloride salt being more active when compared to tramadol base or hydrochloride salt
  • the new drugable forms should combine more than one, most of these advantages.
  • APIs Active Pharmaceutical Ingredients
  • Co-crystals are a specific type of crystalline form which provide a new avenue to modulate the API form and thus to modulate API properties.
  • Co-crystals contain an API and at least one other component which crystallize together. Selection of the other component helps determine whether a co-crystal will form and what properties the co-crystal will have.
  • a polymorph, solvate, hydrate or amorphous form of an API can modulate stability, solubility, and hygroscopicity
  • a co-crystal can modulate those same properties.
  • the main object of the present invention is a co-crystal comprising tramadol either as a free base or as a physiologically acceptable salt and at least one NSAID.
  • “Drugable form (of tramadol)” as used herein is defined as any form (salt, amorphous crystal, solution, dispersion, mixture etc,) that tramadol might take which still can be formulated into a pharmaceutical formulation usable as a medicament to treat a disease or a symptom, especially pain.
  • Co-Crystal as used herein is defined as a crystalline material comprising two or more compounds at ambient temperature (20 to 25° C., preferably 20° C.), of which at least two are held together by weak interaction, wherein at least one of the compounds is a co-crystal former.
  • Weak interaction is being defined as an interaction which is neither ionic nor covalent and includes for example: hydrogen bonds, van der Weals forces, and ⁇ - ⁇ interactions.
  • Solvates of tramadol that do not further comprise a co-crystal former are not co-crystals according to the present invention.
  • the co-crystals may however, include one or more solvate molecules in the crystalline lattice.
  • co-crystal is a multiple component crystal in which all components are solid under ambient conditions when in their pure form. These components consist of a target molecule or ion and a molecular co-crystal former(s); when in a co-crystal, they coexist at a molecular level within a single crystal”.
  • Co-crystal former as use herein is defined as a molecule being an active agent selected from NSAIDs, and with which tramadol is able to form co-crystals.
  • “Active agents” are APIs which show a pharmaceutical effect and thus can be identified as being pharmaceutically active. In a more narrow sense this definition is encompassing all APIs being marketed or under clinical trial for the treatment of diseases. “Active agents with analgesic activity” are APIs (Active Pharmaceutical Ingredients) which show efficacy in well-known animal models of pain and thus can be identified as being analgesics. In a more narrow sense this definition is encompassing all APIs being marketed or under clinical trial for a labelling including an indication falling under the definition of pain, including also migraine.
  • indications might include acute pain, chronic pain, neuropathic pain, hyperalgesia, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy, osteoarthritis or fibromyalgia and all their subforms.
  • active agents with analgesic activity include NSAIDs like naproxen or ibuprofen, pregabalin or tramadol and its N-desmethyl-metabolite.
  • Pain is defined by the International Association for the Study of Pain (IASP) as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage (IASP, Classification of chronic pain, 2 nd Edition, IASP Press (2002), 210). Even though pain is always subjective its causes or syndromes can be classified.
  • IASP International Association for the Study of Pain
  • allodynia is defined as “a pain due to a stimulus which does not normally provoke pain” (IASP, Classification of chronic pain, 2 nd Edition, IASP Press (2002), 210). Even though the symptoms of allodynia are most likely associated as symptoms of neuropathic pain this is not necessarily the case so that there are symptoms of allodynia not connected to neuropathic pain though rendering allodynia in some areas broader than neuropathic pain.
  • the IASP further draws the following difference between “allodynia”, “hyperalgesia” and “hyperpathia” (IASP, Classification of chronic pain, 2 nd Edition, IASP Press (2002), 212):
  • Neurode is defined as “a primary lesion or dysfunction in the nervous system” (IASP, Classification of chronic pain, 2 nd Edition, IASP Press (2002), 211). Neuropathic pain may have central or peripheral origin.
  • Sciatica or “sciatic neuritis is defined herein as a set of symptoms including pain that derive from irritation of the sciatic nerve or its roots,
  • “Frozen shoulder” or “adhesive capsulitis” is defined herein as a symptom wherein the connective tissue surrounding the shoulder joint or the shoulder capsule itself, is causing chronic pain, becoming inflamed and stiff.
  • “Ankylosing spondylitis” or “Morbus Bechterew” is a chronic, inflammatory arthritis and autoimmune disease. It mainly affects joints in the spine and the sacroilium in the pelvis, causing eventual fusion of the spine.
  • the NSAID has at least one functional group from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
  • the NSAID has at least one functional group from the group consisting of alcohol, thiol, ester, carboxylic acid, primary amine, secondary amine, tertiary amine.
  • the NSAID has at least one functional group from the group consisting of alcohol, ester, or carboxylic acid.
  • the NSAID/s is/are chosen in such a way that if compared to either tramadol alone, or to a mixture of tramadol and the corresponding active agent/s:
  • Matture of tramadol and the corresponding active agent/s is defined as a mixture of the active agent or agents in question (the NSAID/s) with tramadol which is only a physical mixture without any coupling forces between the compounds and thus neither includes salts nor another co-crystal.
  • the molar ratio between tramadol and the NSAID is different from 1. This might have the advantage of allowing the development of a non-equimolar ratio between tramadol and the active agent/s in a fixed dose with all the advantages of the co-crystal.
  • NSAIDs have analgesic activity in a number of pain symptoms, with acetyl salicylic acid known under its trademark aspirin—despite being more than 100 years old—being an outstandingly used pharmaceutical.
  • Aspirin other NSAIDs (and COX—INHIBITORS) whose use generally is also centered on anti-inflammatory action like Ibuprofen, naproxen or diclofenac are among the worldwide most frequently applied pharmaceutical compounds.
  • COX cyclooxygenase
  • Preferred NSAIDs are those with a carboxylic acid function. Preferred examples include salicylates, anthranilates, arylacetic acids/arylalkanoic acids, and arylpropionic acids.
  • paracetamol/acetaminophen is to be considered an NSAID.
  • paracetamol/acetaminophen is not considered an NSAID and is therefore excluded/disclaimed from the (list of) NSAIDs (Co-crystal formers) according to this invention.
  • the NSAID is selected from:
  • NSAIDs which have at least one stereogenic center are to be understood as being included herein in their racemic form or as diastereoisomers or enantiomers or mixtures thereof.
  • the NSAID is a Coxib, a selective COX-2 inhibitor. Therefore, another preferred embodiment of the invention is a pharmaceutical compound comprising Tramadol and at least one COX-inhibitor selected from an NSAID being a Coxib. Examples of Coxibs are: celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, valdecoxib, and cimicoxib.
  • a pharmaceutical compound comprising tramadol and celecoxib, preferably a pharmaceutical compound comprising (rac)-tramadol.HCl and celecoxib.
  • the NSAID is selected from:
  • salt is to be understood as meaning any form of tramadol or the NSAID according to the invention in which this assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution.
  • a counter-ion a cation or anion
  • complexes of tramadol or the NSAID with other molecules and ions in particular complexes which are complexed via ionic interactions. This also includes physiologically acceptable salt.
  • solvate is to be understood as meaning any form of the tramadol or NSAID in which the compound has attached to it via non-covalent binding another molecule (most likely a polar solvent) especially including hydrates and alcohol solvates, e.g. methanol solvate.
  • a highly interesting NSAID to be the co-crystal former with tramadol is the marketed drug naproxen.
  • the chemical name of its (S)-enantiomer, the marketed (S)-naproxen, is (S)-(6-methoxy-2-naphtyl)propionic acid, and which is also described as a physiologically acceptable salt. It has an empirical formula of C 14 H 14 O 3 , an Mp of 153° C. and a pKa of 4.2.
  • NSAID is naproxen, its enantiomers or salts thereof.
  • NSAID is (S)-naproxen or (R)-naproxen.
  • Another embodiment of the invention relates to a co-crystal according to the invention, wherein the tramadol is ( ⁇ )-tramadol or (+)-tramadol.
  • tramadol and especially its enantiomers (+)-tramadol and ( ⁇ )-tramadol form co-crystals with naproxen, especially with (S)-naproxen and (R)-naproxen.
  • co-crystals obtained have a specific stoichiometry which depends upon the structure of each co-crystal forming NSAID.
  • the molecular ratio between tramadol and naproxen is 1 to 2.
  • co-crystal according to the invention is selected from
  • the molecular ratio between the tramadol and naproxen is 1:2.
  • a co-crystal with a molecular ratio between the tramadol and naproxen of 1:2 comprising ( ⁇ )-tramadol either as a free base or as a physiologically acceptable salt and (S)-naproxen or comprising (+)-tramadol either as a free base or as a physiologically acceptable salt and (R)-naproxen, or mixture of enantiomers of these co-crystals
  • the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [20] at 4.3, 8.7, 9.5, 10.2, 10.6, 11.3, 12.1, 12.7, 13.2, 13.7, 14.3, 14.6, 14.8, 15.5, 15.7, 16.0, 16.2, 17.0, 17.4, 17.9, 18.1, 18.7, 19.1, 19.4, 19.7, 20.1, 20.5, 20.8, 21.1, 21.4, 21.6 and 21.8 [°].
  • the 2 ⁇ values were obtained using copper radiation (Cu K ⁇ 1 1.54060 ⁇ ).
  • a co-crystal with a molecular ratio between the tramadol and naproxen of 1:2 comprising ( ⁇ )-tramadol either as a free base or as a physiologically acceptable salt and (S)-naproxen or comprising (+)-tramadol either as a free base or as a physiologically acceptable salt and (R)-naproxen, or mixture of enantiomers of these co-crystals
  • the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3247, 2942, 1699, 1633, 1605, 1583, 1485, 1380, 1271, 1223, 1160, 1029, 851, 789 and 704 cm ⁇ 1 .
  • a co-crystal with a molecular ratio between the tramadol and naproxen of 1:2 comprising ( ⁇ )-tramadol either as a free base or as a physiologically acceptable salt and (S)-naproxen or comprising (+)-tramadol either as a free base or as a physiologically acceptable salt and (R)-naproxen, or enantiomeric mixtures of these co-crystals
  • the co-crystal has a monoclinic unit cell with the following dimensions:
  • a co-crystal with a molecular ratio between the tramadol and naproxen of 1:2 comprising ( ⁇ )-tramadol either as a free base or as a physiologically acceptable salt and (S)-naproxen or comprising (+)-tramadol either as a free base or as a physiologically acceptable salt and (R)-naproxen, or enantiomeric mixtures of these co-crystals
  • the endothermic sharp peak of the co-crystal corresponding to the melting point has an onset at 82° C.
  • a co-crystal with a molecular ratio between the tramadol and naproxen of 1:2 comprising ( ⁇ )-tramadol either as a free base or as a physiologically acceptable salt and (S)-naproxen or comprising (+)-tramadol either as a free base or as a physiologically acceptable salt and (R)-naproxen, or enantiomeric mixtures of these co-crystals
  • the endothermic sharp peak of the co-crystal corresponding to the melting point has an onset at 82° C. to 84° C.
  • a co-crystal with a molecular ratio between the tramadol and naproxen of 1:2 according to the invention comprising (+)-tramadol either as a free base or as a physiologically acceptable salt and (R)-naproxen is in the form of a methanol solvate.
  • the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 ⁇ ] at 4.1, 6.6, 9.0, 9.2, 10.4, 11.0, 11.5, 12.3, 12.5, 12.7, 13.0, 13.2, 13.8, 14.9, 15.4, 16.2, 17.2, 17.6, 18.1, 18.5, 19.1, 19.3, 19.6, 19.9, 20.1, 20.4, 20.9, 21.0, 21.5, 22.0, 22.3 and 22.6 [°].
  • the 2 ⁇ values were obtained using copper radiation (Cu K ⁇ 1 1.54060 ⁇ ).
  • the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3523, 3151, 2928, 2861, 2465, 1706, 1632, 1603, 1567, 1485, 1461, 1445, 1417, 1388 and 1362 cm ⁇ 1 .
  • tramadol forms co-crystals with (S)-naproxen.
  • co-crystals obtained have a specific stoichiometry which depends upon the structure of each co-crystal former.
  • the molecular ratio between Tramadol and (S)-naproxen is 1 to 2.
  • Coxibs Highly interesting NSAID to be the co-crystal formers with tramadol are the Coxibs. The most important of these is the marketed drug celecoxib. Its chemical name is 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-pyrazol-1-yl]benzenesulfonamide. It has an empirical formula of C 17 H 14 F 3 N 3 O 2 S.
  • the NSAID is selected from:
  • Another very preferred aspect of the invention relates to a co-crystal according to the invention, wherein the NSAID is celecoxib or salts thereof.
  • tramadol and especially the racemate—forms co-crystals with celecoxib.
  • co-crystals obtained have a specific stoichiometry which depends upon the structure of each co-crystal forming NSAID.
  • the molecular ratio between tramadol and celecoxib is 1 to 1.
  • co-crystal according to the invention is selected from
  • the molecular ratio between the (rac)-tramadol.HCl and celecoxib is 1:1.
  • the co-crystal shows a Powder X-Ray Diffraction pattern with peaks [2 ⁇ ] at 7.1, 9.3, 10.2, 10.7, 13.6, 13.9, 14.1, 15.5, 16.1, 16.2, 16.8, 17.5, 18.0, 19.0, 19.5, 19.9, 20.5, 21.2, 21.3, 21.4, 21.8, 22.1, 22.6, 22.7, 23.6, 24.1, 24.4, 25.2, 26.1, 26.6, 26.8, 27.4, 27.9, 28.1, 29.1, 29.9, 30.1, 31.1, 31.3, 31.7, 32.5, 32.8, 34.4, 35.0, 35.8, 36.2 and 37.2 [°].
  • the 2 ⁇ values were obtained using copper radiation (Cu K ⁇ 1 1.54060 ⁇ ).
  • the co-crystal shows a Fourier Transform Infra Red pattern with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1 (m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1 (m), 786.5 (m) 625.9 (m) cm ⁇ 1 .
  • the co-crystal has an orthorhombic unit cell with the following dimensions:
  • the endothermic sharp peak of the co-crystal corresponding to the melting point has an onset at 164° C.
  • Ambient temperature is defined here as a temperature between 20 and 25° C., preferably being 20° C.
  • the solvents usable in these processes include water or organic solvents, preferably solvents selected from acetone, isobutyl acetate, acetonitrile, ethyl acetate, 2-butanol, dimethylcarbonate, chlorobenzene, butylether, diisopropylether, dimethylformamide, ethanol, water, hexane (also cyclohexane), isopropanol, methyl ethyl ketone (also methyl isobutyl-ketone), methanol, methyl t-butyl ether, 3-pentanone, toluene and 1,1,1-trichloroethane, most preferably including alcohols, like ethanol. It is preferable—but not necessary—that the solvents in steps (a) and (c) are identical.
  • the molecular ratio between tramadol and the NSAID lies between 4:1 to 1:4, preferably from 3:1 to 1:3 and more preferably from 1:1 to 1:2.
  • the tramadol-solution in step (b) has a concentration of between 3M and 0.01 M.
  • the parts of the co-crystal according to the invention are well-known drugs with analgesic properties sometimes used for a long time worldwide. Due to this a further object of the present invention is a medicament comprising a co-crystal according to the invention.
  • the invention also concerns a medicament comprising at least one co-crystal according to the invention as described above and optionally one or more pharmaceutically acceptable excipients.
  • the invention also relates to a pharmaceutical composition that comprises a therapeutically effective amount of the co-crystal according to the invention in a physiologically acceptable medium.
  • PKPD Pharmacokinetic/Pharmacodynamic
  • these co-crystals would be formulated into a convenient pharmaceutical formulation or a medicament. Accordingly, a desirable advantage of a co-crystal of tramadol, would show improved pharmaceutical properties and features, especially when compared to the free base or tramadol hydrochloride.
  • the co-crystal of tramadol according to the invention should desirably show at least one, preferably more, of the following features:
  • the medicament or pharmaceutical compositions according to the present invention may be in any form suitable for the application to humans and/or animals, preferably humans including infants, children and adults and can be produced by standard procedures known to those skilled in the art.
  • the medicament of the present invention may for example be administered parenterally, including intramuscular, intraperitoneal, or intravenous injection, transmucosal or sublingual application; or orally, including administration as tablets, pellets, granules, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, sprays or as reconstituted dry powdered form with a liquid medium.
  • the medicaments according to the present invention may contain 1-60% by weight of one or more of the co-crystals as defined herein and 40-99% by weight of one or more auxiliary substances (additives/excipients).
  • compositions of the present invention may also be administered topically or via a suppository.
  • the daily dosage for humans and animals may vary depending on factors that have their basis in the respective species or other factors, such as age, sex, weight or degree of illness and so forth.
  • the daily dosage for humans preferably is in the range of 5 to 500 milligrams of tramadol to be administered during one or several intakes per day.
  • a further aspect of the invention relates to the use of co-crystal according to the invention as described above for the treatment of pain, preferably acute pain, chronic pain, neuropathic pain, hyperalgesia, allodynia or cancer pain, including diabetic neuropathy or osteoarthritis or fibromyalgia.
  • a further aspect of the invention relates to the use of co-crystal according to the invention as described above for the treatment of pain, preferably acute pain, chronic pain, neuropathic pain, severe to moderate pain, hyperalgesia, allodynia or cancer pain, including diabetic neuropathy, osteoarthritis, fibromyalgia; rheumatoid arthritis, ankylosing spondylitis, frozen shoulder or sciatica.
  • these uses are provided for in form of a medicament or a pharmaceutical composition according to the invention as described above.
  • Another object of the current invention is a method of treatment of pain, preferably acute pain, chronic pain, neuropathic pain, hyperalgesia, allodynia or cancer pain, including diabetic neuropathy or osteoarthritis or fibromyalgia, by providing to a patient in need thereof a sufficient amount of a co-crystal according to the invention as described above.
  • the co-crystal according to the invention is provided in physiologically suitable form like e.g. in form of a medicament or a pharmaceutical composition according to the invention as described above.
  • FIG. 1 Powder X-Ray diffraction pattern of ( ⁇ )-tramadol-(S)-naproxen 1:2 co-crystal.
  • FIG. 2 DSC analysis of ( ⁇ )-tramadol-(S)-naproxen 1:2 co-crystal.
  • FIG. 3 TG analysis of ( ⁇ )-tramadol-(S)-naproxen 1:2 co-crystal.
  • FIG. 4 Structure of the unit cell of the ( ⁇ )-tramadol-(S)-naproxen 1:2 co-crystal obtained by SCXRD analysis showing four molecules of (S)-naproxen and two molecules of ( ⁇ )-tramadol.
  • FIG. 5 Powder X-Ray diffraction pattern of the (+)-tramadol-(R)-naproxen 1:2 methanol solvate co-crystal.
  • FIG. 6 DSC analysis of (+)-tramadol-(R)-naproxen 1:2 methanol solvate co-crystal.
  • FIG. 7 TG analysis of the (+)-tramadol-(R)-naproxen 1:2 methanol solvate co-crystal.
  • FIG. 8 Powder X-Ray diffraction pattern of the (rac)-tramadol.HCl-celecoxib 1:1 co-crystal.
  • FIG. 9 DSC analysis of the (rac)-tramadol.HCl-celecoxib 1:1 co-crystal.
  • FIG. 10 TG analysis of the (rac)-tramadol.HCl-celecoxib 1:1 co-crystal.
  • FIG. 11 Structure of the unit cell of the (rac)-tramadol.HCl-celecoxib 1:1 co-crystal obtained by SCXRD analysis showing two molecules of celecoxib and two molecules of tramadol.
  • Powder diffraction patterns were acquired on a D8 Advance Series 2Theta/Theta powder diffraction system using Cu K ⁇ -radiation in transmission geometry.
  • the system is equipped with a V ⁇ hacek over (A) ⁇ NTEC-1 single photon counting PSD, a Germanium monochromator, a ninety positions auto changer sample stage, fixed divergence slits and radial soller.
  • the FTIR spectra (ATR) of the co-crystal of ( ⁇ )-tramadol-(S)-naproxen were recorded using a Bruker Tensor 27, equipped with a MKII golden gate single reflection ATR system, a mid-infrared source as the excitation source and a DTGS detector.
  • the spectra were acquired in 32 scans at a resolution of 4 cm ⁇ 1 .
  • the sample of ( ⁇ )-tramadol-(S)-naproxen co-crystal (1:2) shows a Fourier Transform Infra Red spectrum (ATR) with absorption bands ⁇ max at 3247, 2942, 1699, 1633, 1605, 1583, 1485, 1380, 1271, 1223, 1160, 1029, 851, 789 and 704 cm ⁇ 1 .
  • ATR Fourier Transform Infra Red spectrum
  • the endothermic peak of the DSC analysis of ( ⁇ )-tramadol-(S)-naproxen co-crystal (1:2) corresponds to the melting point with an onset at 82° C., see FIG. 2 .
  • Thermogravimetric analyses were recorded in a Mettler Toledo SDTA851e. Samples of 3-4 mg were weighted into 40 ⁇ L aluminium crucibles with a pinhole lid, and heated at 10° C./min from 30 to 500° C., under nitrogen (80 mL/min).
  • the TG analysis of the ( ⁇ )-tramadol-(S)-naproxen co-crystal (1:2) according to the invention does not show weight loss at temperatures below the melting point (see FIG. 3 ).
  • the crystal structure was determined from single crystal X-ray diffraction data.
  • the measured crystal obtained from the preparation according to example 1 was selected using a Zeiss stereomicroscope using polarized light and prepared under inert conditions immersed in perfluoropolyether as protecting oil for manipulation.
  • (+)-tramadol-(R)-naproxen (1:2) co-crystal obtained according to example 2 was fully characterised by 1 H-NMR, FTIR, powder X-Ray diffraction, DSC and TG.
  • (+)-tramadol-(R)-naproxen (1:2) methanol solvate co-crystal obtained according to example 3 was fully characterised by 1 H-NMR, FTIR, powder X-Ray diffraction, DSC and TG (see FIGS. 5 to 8 ).
  • Powder X-ray Diffraction (PXRD) Pattern of a (+)-Tramadol-(R)-Naproxen Methanol Solvate (1:2) Co-Crystal See FIG. 5):
  • Powder diffraction patterns were acquired on a D8 Advance Series 2Theta/Theta powder diffraction system using Cu K ⁇ -radiation in transmission geometry.
  • the system is equipped with a V ⁇ hacek over (A) ⁇ NTEC-1 single photon counting PSD, a Germanium monochromator, a ninety positions auto changer sample stage, fixed divergence slits and radial soller.
  • the FTIR spectra (ATR) of the (+)-tramadol-(R)-naproxen methanol solvate (1:2) co-crystal were recorded using a Bruker Tensor 27, equipped with a MKII golden gate single reflection ATR system, a mid-infrared source as the excitation source and a DTGS detector.
  • the spectra were acquired in 32 scans at a resolution of 4 cm ⁇ 1 .
  • (+)-tramadol-(R)-naproxen methanol solvate (1:2) co-crystal shows a Fourier Transform Infra Red spectrum (ATR) with absorption bands ⁇ max at 3523, 3151, 2928, 2861, 2465, 1706, 1632, 1603, 1567, 1485, 1461, 1445, 1417, 1388 and 1362 cm ⁇ 1 .
  • ATR Infra Red spectrum
  • Thermogravimetric analyses were recorded in a Mettler Toledo SDTA851e. Samples of 3-4 mg were weighted into 40 ⁇ L aluminium crucibles with a pinhole lid, and heated at 10° C./min from 30 to 500° C., under nitrogen (80 mL/min).
  • the TG analysis of the (+)-tramadol-(R)-naproxen methanol solvate (1:2) co-crystal according to the invention does show weight loss of 7.2% between 40 and 140° C. followed by decomposition starting at 160° C. (see FIG. 7 ).
  • Proton nuclear magnetic resonance analyses were recorded in methanol-d 4 in a Varian Mercury 400 spectrometer, equipped with a broadband probe ATB 1H/19F/X of 5 mm. Spectra were acquired dissolving 5-10 mg of sample in 0.6 mL of deuterated solvent.
  • FTIR spectra were recorded using a Thermo Nicolet Nexus 870 FT-IR, equipped with a beamsplitter KBr system, a 35 mW He—Ne laser as the excitation source and a DTGS KBr detector. The spectra were acquired in 32 scans at a resolution of 4 cm 1 .
  • the sample shows a Fourier Transform Infra Red spectrum with absorption bands at 3481.6 (m), 3133.5 (m), 2923.0 (m), 2667.7 (m), 1596.0 (m), 1472.4 (m), 1458.0 (m), 1335.1(m), 1288.7 (m), 1271.8 (m), 1168.7 (s), 1237.3 (m), 1168.7 (s), 1122.6 (s), 1100.9 (m), 1042.2 (m), 976.8 (m), 844.6 (m), 820.1(m), 786.5 (m) 625.9 (m) cm ⁇ 1 .
  • the novel type of crystal of the present invention is characterized in that the endothermic sharp peak corresponding to the melting point has an onset at 164.44° C. (fusion enthalpy ⁇ 93.56 J/g), measured by DSC analysis (10° C./min) (see FIG. 9 ).
  • thermogravimetric analyzer Mettler TGA/SDTA851 e Thermogravimetric analyses were recorded in a thermogravimetric analyzer Mettler TGA/SDTA851 e . A sample of 3.0560 mg was weighed into a 70 ⁇ L alumina crucible with a pinhole lid and was heated at 10° C./min from 30 to 200° C., under nitrogen (50 mL/min).
  • the TG analysis of the crystalline form according to the invention shows insignificant weight loss between 30 and 200° C.
  • the crystal structure was determined from single crystal X-ray diffraction data.
  • the colourless prism used (0.33 ⁇ 0.16 ⁇ 0.11 mm) was obtained from the crystallization of a seeded solution in heptane and IPA of equimolar amounts of (rac)-tramadol hydrochloride and celecoxib.
  • FIG. 12 The crystal structure is depicted in FIG. 12 (only half of the unitcell contents is shown, hydrogen atoms have been omitted for clarity; program used: Mercury 2.2, C. F. Macrae, I. J. Bruno, J. A. Chisholm, P. R. Edgington, P. McCabe, E. Pidcock, L. Rodriguez-Monge, R. Taylor, J. van de Streek and P. A. Wood, J. Appl. Cryst., 41, 2008, 466-470).
  • the objective is to measure plasma exposure in rat of (rac)-tramadol.HCl and celecoxib by means of AUC determination of the co-crystal of (rac)-tramadol.HCl—celecoxib (1:1) of the present invention, and comparing it with each active principle of the co-crystal and the fixed combination of the two active principles.
  • Bioavailability of (rac)-tramadol.HCl—celecoxib co-crystal is compared to those obtained after administration of tramadol.HCl plus celecoxib, combined and separately, to rats by oral route.
  • Products with an equivalent particle size are orally administered by means of rodent capsules at a dose level of 25 mg/kg of co-crystal and at an equivalent dose level of comparators (11 mg tramadol.HCl/kg, 14 mg celecoxib/kg).
  • Blood from rats is extracted at the following time points: predose, 15, 30, 45 min, 1, 1.5, 2, 3, 4, 5, 6, 8 and 24 h. Plasma is isolated by centrifugation, purified by SPE and plasma levels are determined by LC-MS-MS. Pharmacokinetic parameters are calculated using non-compartmental pharmacokinetic analysis.
US13/124,027 2008-10-17 2009-10-16 CO-CRYSTALS OF TRAMADOL AND NSAIDs Abandoned US20110257134A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08384012.4 2008-10-17
EP20080384012 EP2177215A1 (de) 2008-10-17 2008-10-17 Co-Kristalle von Tramadol und NSARs
PCT/EP2009/007451 WO2010043412A1 (en) 2008-10-17 2009-10-16 Co-crystals of tramadol and nsaids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/007451 A-371-Of-International WO2010043412A1 (en) 2008-10-17 2009-10-16 Co-crystals of tramadol and nsaids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/324,448 Division US9393220B2 (en) 2008-10-17 2014-07-07 Co-crystals of tramadol and NSAIDs

Publications (1)

Publication Number Publication Date
US20110257134A1 true US20110257134A1 (en) 2011-10-20

Family

ID=40673614

Family Applications (10)

Application Number Title Priority Date Filing Date
US13/124,027 Abandoned US20110257134A1 (en) 2008-10-17 2009-10-16 CO-CRYSTALS OF TRAMADOL AND NSAIDs
US13/395,021 Active US8598152B2 (en) 2008-10-17 2010-04-19 Co-crystals of tramadol and coxibs
US14/066,127 Active US9012440B2 (en) 2008-10-17 2013-10-29 Co-crystals of tramadol and coxibs
US14/324,448 Active US9393220B2 (en) 2008-10-17 2014-07-07 Co-crystals of tramadol and NSAIDs
US14/665,055 Abandoned US20150196503A1 (en) 2008-10-17 2015-03-23 Co-crystals of tramadol and coxibs
US14/665,060 Abandoned US20150196504A1 (en) 2008-10-17 2015-03-23 Co-crystals of tramadol and coxibs
US15/207,694 Active US10238668B2 (en) 2008-10-17 2016-07-12 Co-crystals of tramadol and coxibis
US15/231,915 Active US10245276B2 (en) 2008-10-17 2016-08-09 Co-crystals of tramadol and coxibs
US16/275,437 Active US10548909B2 (en) 2008-10-17 2019-02-14 Co-crystals of tramadol and coxibs
US16/720,574 Active US11478488B2 (en) 2008-10-17 2019-12-19 Co-crystals of tramadol and coxibs

Family Applications After (9)

Application Number Title Priority Date Filing Date
US13/395,021 Active US8598152B2 (en) 2008-10-17 2010-04-19 Co-crystals of tramadol and coxibs
US14/066,127 Active US9012440B2 (en) 2008-10-17 2013-10-29 Co-crystals of tramadol and coxibs
US14/324,448 Active US9393220B2 (en) 2008-10-17 2014-07-07 Co-crystals of tramadol and NSAIDs
US14/665,055 Abandoned US20150196503A1 (en) 2008-10-17 2015-03-23 Co-crystals of tramadol and coxibs
US14/665,060 Abandoned US20150196504A1 (en) 2008-10-17 2015-03-23 Co-crystals of tramadol and coxibs
US15/207,694 Active US10238668B2 (en) 2008-10-17 2016-07-12 Co-crystals of tramadol and coxibis
US15/231,915 Active US10245276B2 (en) 2008-10-17 2016-08-09 Co-crystals of tramadol and coxibs
US16/275,437 Active US10548909B2 (en) 2008-10-17 2019-02-14 Co-crystals of tramadol and coxibs
US16/720,574 Active US11478488B2 (en) 2008-10-17 2019-12-19 Co-crystals of tramadol and coxibs

Country Status (27)

Country Link
US (10) US20110257134A1 (de)
EP (2) EP2177215A1 (de)
JP (1) JP5645830B2 (de)
KR (1) KR101679400B1 (de)
CN (1) CN102186465B (de)
AU (1) AU2009304235B2 (de)
BR (1) BRPI0920358A2 (de)
CA (1) CA2737754C (de)
CY (1) CY1118374T1 (de)
DK (1) DK2349238T3 (de)
ES (1) ES2603962T3 (de)
HR (1) HRP20161526T1 (de)
HU (1) HUE030976T2 (de)
IL (1) IL211785A (de)
IN (1) IN2012DN01435A (de)
LT (1) LT2349238T (de)
MX (1) MX336318B (de)
MY (1) MY156285A (de)
NZ (1) NZ591873A (de)
PL (1) PL2349238T3 (de)
PT (1) PT2349238T (de)
RU (1) RU2599717C2 (de)
SI (1) SI2349238T1 (de)
SM (1) SMT201600439B (de)
UA (1) UA109534C2 (de)
WO (1) WO2010043412A1 (de)
ZA (1) ZA201102762B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150374650A1 (en) * 2013-02-14 2015-12-31 Laboratorios Menarini Sa Pharmaceutical compositions containing dexketoprofen and tramadol

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (de) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-Kristalle von Tramadol und NSARs
PL2488169T3 (pl) * 2009-10-16 2013-06-28 Esteve Pharmaceuticals Sa Kokryształy tramadolu i koksybów
EP2392319A1 (de) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmazeutische Zusammensetzung enthaltend Cokristalle aus Tramadol und einem Coxib
WO2012009262A2 (en) * 2010-07-12 2012-01-19 Yung Shin Pharm. Ind. Co., Ltd. Diclofenac salt of tramadol
DE102010063609A1 (de) * 2010-12-20 2012-06-21 Awd.Pharma Gmbh & Co. Kg Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3yl)-carbamidsäureethylester und einer Arylpropionsäure
KR101888852B1 (ko) 2011-12-02 2018-09-21 삼성전자주식회사 휴대용 단말기에서 다이버시티 서비스를 제공하기 위한 장치 및 방법
GB201222287D0 (en) * 2012-12-11 2013-01-23 Ct For Process Innovation Ltd Methods for making active crystalline materials
RU2542100C1 (ru) * 2013-12-24 2015-02-20 Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской Академии Наук (ИХС РАН) Сокристаллическая форма теофиллина с дифлунисалом или диклофенаком
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN104592009B (zh) * 2015-02-09 2017-02-22 黑龙江大学 萘普生药物共晶及其制备方法
US9693949B1 (en) * 2015-12-22 2017-07-04 Revogenex Ireland Ltd Intravenous administration of tramadol
MX2016006464A (es) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
AU2018230350A1 (en) * 2017-03-08 2019-09-26 Intercept Pharmaceuticals, Inc Crystalline forms of obeticholic acid
MX2018003456A (es) 2017-12-21 2019-09-06 Gruenenthal Gmbh Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor.
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
US11510926B2 (en) 2018-05-31 2022-11-29 The Royal Institution For The Advancement Of Learning/Mcgill University Pharmaceutical salts/co-crystals of pentoxifylline, clonidine and linsidomine with caffeic, protocatechuic or alpha-lipoic acid an use thereof for treatment of pain
WO2020039456A1 (en) * 2018-08-20 2020-02-27 Mylan Laboratories Limited Tramadol hbr-celecoxib co-crystal
WO2020121326A1 (en) 2018-12-13 2020-06-18 Mylan Laboratories Limited Amorphous (rac)-tramadol.hcl-celecoxib (1:1)
CA3137381A1 (en) * 2019-05-14 2020-11-19 Esteve Pharmaceuticals, S.A. Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol
EP4169903A1 (de) * 2021-10-25 2023-04-26 Dompe' Farmaceutici S.P.A. Co-kristalle von nichtsteroidalen entzündungshemmenden arzneimitteln, lysin und gabapentin, pharmazeutische zusammensetzungen und deren medizinische verwendung
KR20240027436A (ko) * 2022-08-23 2024-03-04 대원제약주식회사 펠루비프로펜 및 트라마돌의 이온결합 화합물, 이를 포함하는 조성물, 및 이의 제조 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051685A1 (en) * 1999-03-01 2000-09-08 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and a selective cox-2 inhibitor drug
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20070026078A1 (en) * 2002-02-15 2007-02-01 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions
US20070141144A1 (en) * 2004-05-28 2007-06-21 Roberts Michael S Oral delivery system

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
WO1993004675A1 (en) 1991-09-06 1993-03-18 Mcneilab, Inc. Composition comprising a tramadol material and acetaminophen and its use
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CA2276945C (en) 1993-11-30 2006-08-01 G.D. Searle & Co. Tricyclic-substituted pyrazolyl benzenesulfonamides and pharmaceutical compositions thereof
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
DE69739003D1 (de) 1996-04-12 2008-10-30 Searle Llc Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren
PL187848B1 (pl) 1996-07-18 2004-10-29 Merck Frosst Canada Inc Podstawione pirydyny, kompozycja farmaceutyczna, podstawione pirydyny jako selektywne inhibitory cyklooksygenazy-2 oraz zastosowanie podstawionych pirydyn
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
EP1413294B1 (de) 2001-07-27 2010-09-29 Astellas Pharma Inc. Zusammensetzung enthaltend feine Körner mit verzögerter Freisetzung für in der Mundhöhle schnell zerfallende Tabletten
WO2004078163A2 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CN100418533C (zh) 2002-02-19 2008-09-17 阿德科克因格拉姆有限公司 环加氧酶-2抑制剂和阿片剂的药物组合体
EP1537258B9 (de) 2002-07-17 2008-10-29 S.O.I.Tec Silicon on Insulator Technologies Verfahren zur herstellung von substraten, insbesondere für die optik, elektronik und optoelektronik
CN1245968C (zh) 2002-10-09 2006-03-22 新疆特丰药业股份有限公司 一种萘普生钠缓释片剂的制备方法
JP4469846B2 (ja) 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
EP1727520A2 (de) 2003-12-09 2006-12-06 Medcrystalforms, Llc Verfahren zur herstellung von mischphasen-kokristallen mit wirkstoffen
DE102006056458A1 (de) * 2006-11-28 2008-05-29 Grünenthal GmbH Arzneimittelzubereitung von Tramadol und Acetaminophen
WO2008085674A1 (en) 2007-01-04 2008-07-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising celecoxib co-crystals
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
EP2022778A1 (de) * 2007-08-07 2009-02-11 Laboratorios del Dr. Esteve S.A. Kristalline Form von (R,R)-Tramadol-(S)-Naproxensalz
CN105254662A (zh) 2008-05-20 2016-01-20 阿索尔达治疗公司 水溶性对乙酰氨基酚类似物
EA023435B1 (ru) 2008-09-06 2016-06-30 Бионевия Фармасьютикалс, Инк. Фармацевтическая композиция, включающая новый холиновый сокристалл эпалрестата
EP2177215A1 (de) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-Kristalle von Tramadol und NSARs
EP2311446A1 (de) 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Zusammensetzungen, die Tramadol und Celecoxib umfassen, zur Behandlung von Schmerzen
PL2488169T3 (pl) * 2009-10-16 2013-06-28 Esteve Pharmaceuticals Sa Kokryształy tramadolu i koksybów
CN104817501B (zh) 2009-10-16 2017-09-22 埃斯蒂文博士实验室股份有限公司 曲马多与昔布类的共晶体
CA2797829A1 (en) * 2010-05-07 2011-11-10 Carefusion 2200, Inc. Method of producing pleurodesis
EP2392319A1 (de) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmazeutische Zusammensetzung enthaltend Cokristalle aus Tramadol und einem Coxib
CA3137381A1 (en) * 2019-05-14 2020-11-19 Esteve Pharmaceuticals, S.A. Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051685A1 (en) * 1999-03-01 2000-09-08 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and a selective cox-2 inhibitor drug
US20070026078A1 (en) * 2002-02-15 2007-02-01 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20070141144A1 (en) * 2004-05-28 2007-06-21 Roberts Michael S Oral delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Merck & Co. Inc. v. Biocraft Laboratories Inc., 10 USPQ2d 1843 (Fed. Cir. 1989) (U.S. Court of Appeals Federal Circuit, 1989) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150374650A1 (en) * 2013-02-14 2015-12-31 Laboratorios Menarini Sa Pharmaceutical compositions containing dexketoprofen and tramadol
US9949940B2 (en) * 2013-02-14 2018-04-24 Labortorios Mena Rini SA Pharmaceutical compositions containing dexketoprofen and tramadol

Also Published As

Publication number Publication date
US8598152B2 (en) 2013-12-03
EP2349238B1 (de) 2016-08-24
RU2599717C2 (ru) 2016-10-10
US11478488B2 (en) 2022-10-25
CN102186465A (zh) 2011-09-14
JP2012505847A (ja) 2012-03-08
RU2011119608A (ru) 2012-11-27
US10548909B2 (en) 2020-02-04
CA2737754C (en) 2016-09-20
HUE030976T2 (en) 2017-06-28
US20150196504A1 (en) 2015-07-16
NZ591873A (en) 2012-12-21
SMT201600439B (it) 2017-01-10
IL211785A0 (en) 2011-06-30
JP5645830B2 (ja) 2014-12-24
ES2603962T3 (es) 2017-03-02
US20190231800A1 (en) 2019-08-01
LT2349238T (lt) 2016-12-27
MX336318B (es) 2016-01-14
AU2009304235B2 (en) 2015-05-07
AU2009304235A1 (en) 2010-04-22
US20170000806A1 (en) 2017-01-05
SI2349238T1 (sl) 2017-01-31
PT2349238T (pt) 2016-11-24
UA109534C2 (uk) 2015-09-10
CY1118374T1 (el) 2017-06-28
US9393220B2 (en) 2016-07-19
US20170027965A1 (en) 2017-02-02
IN2012DN01435A (de) 2015-06-05
WO2010043412A1 (en) 2010-04-22
US10238668B2 (en) 2019-03-26
US10245276B2 (en) 2019-04-02
CN102186465B (zh) 2015-09-16
MY156285A (en) 2016-01-29
IL211785A (en) 2016-07-31
US9012440B2 (en) 2015-04-21
EP2349238A1 (de) 2011-08-03
PL2349238T3 (pl) 2017-06-30
US20120172398A1 (en) 2012-07-05
BRPI0920358A2 (pt) 2020-08-11
KR101679400B1 (ko) 2016-11-24
KR20110069860A (ko) 2011-06-23
EP2177215A1 (de) 2010-04-21
US20140350110A1 (en) 2014-11-27
DK2349238T3 (en) 2016-12-12
MX2011003612A (es) 2011-05-10
CA2737754A1 (en) 2010-04-22
US20140057879A1 (en) 2014-02-27
ZA201102762B (en) 2011-12-28
US20150196503A1 (en) 2015-07-16
HRP20161526T1 (hr) 2016-12-16
US20200171055A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
US9393220B2 (en) Co-crystals of tramadol and NSAIDs
US8501802B2 (en) Co-crystals of duloxetine and COX-INHIBITORs for the treatment of pain
US20230057884A1 (en) Co-crystals of tramadol and coxibs
ES2390897B1 (es) Compuestos farmacéuticos de O-desmetil-tramadol e inhibidores de la COX
US20110105443A1 (en) Salts of memantine and cox-inhibitors and their crystal form in the treatment of pain

Legal Events

Date Code Title Description
AS Assignment

Owner name: LABORATORIOS DEL DR. ESTEVE, S.A., SPAIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUSCHMANN, HELMUT HEINRICH;SOLA CARANDELL, LLUIS;BENET BUCHHOLZ, JORDI;AND OTHERS;SIGNING DATES FROM 20110408 TO 20110502;REEL/FRAME:026522/0656

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION